Literature DB >> 23618858

Up-regulation of cyclin-E(1) via proline-mTOR pathway is responsible for HGF-mediated G(1)/S progression in the primary culture of rat hepatocytes.

Kiyomasa Oka1, Wakana Ohya-Shimada, Shinya Mizuno, Toshikazu Nakamura.   

Abstract

Hepatocyte growth factor (HGF) is a key ligand that elicits G1/S progression of epithelial cells, including hepatocytes. Proline is also required for DNA synthesis that is induced by growth factors in primary culture of hepatocytes. However, it remains unknown how proline contributes to the G1/S progression of hepatocytes. The primary culture of rat hepatocytes using HGF plus proline can be a conceptual model for elucidating the molecular linkage of amino acids and growth factors during G1/S progression. Using this in vitro model, we provide evidence that not only induction of cyclin-D1 by HGF but also up-regulation of cyclin-E1 by proline is required for hepatocytes to enter the S-phase. Proline-enhanced cyclin-E1 induction, without changing its mRNA level, is associated with the activation of mammalian target of rapamycin (mTOR)-dependent pathways. Indeed, proline enhanced the ribosomal protein S6 phosphorylations (i.e., mTOR target), concomitantly with an increase in cyclin-E1. Inversely, mTOR-inhibitor, rapamycin suppressed the proline-mediated induction of cyclin-E1. As a result, DNA synthesis of hepatocytes, which was induced by HGF in the presence of proline, was largely abolished by mTOR-inhibitor treatment. Such a co-mitogenic effect of proline was also dependent on collagen synthesis: collagen synthesis inhibitors, such as cis-OH-proline, diminished the proline-induced cyclin-E1, and then the G1/S progression of hepatocytes was also suppressed. Overall, proline-mediated mTOR activation and collagen synthesis were found critical for HGF-induced DNA synthesis, partly via the sufficient accumulation of cyclin-E1. This is the first report to demonstrate the molecular bridge between amino acids and growth factors that drive mitogenic outcomes.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23618858     DOI: 10.1016/j.bbrc.2013.04.052

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1.

Authors:  Yan-Dong Wang; Yong-Jing Su; Jian-Ying Li; Xiang-Chao Yao; Guang-Jiang Liang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

2.  Mechanism study of isoflavones as an anti-retinoblastoma progression agent.

Authors:  Qifeng Wu; He Bai; Chu-Long Huang; Yongming Zhang; Xiayun Zeng; Huan Wan; Wen Zuo; Hai-Ying Wang; Yi-Xin Zeng; Yan-Dong Wang
Journal:  Oncotarget       Date:  2017-07-18

3.  Novel sericin-based hepatocyte serum-free medium and sericin's effect on hepatocyte transcriptome.

Authors:  Yun Huang; Qing Peng; Hai-Yan Li; Zhi-Dong Jia; Yang Li; Yi Gao
Journal:  World J Gastroenterol       Date:  2018-08-14       Impact factor: 5.742

Review 4.  Narrative review of emerging roles for AKT-mTOR signaling in cancer radioimmunotherapy.

Authors:  Changxian Shen; Yuqi He; Qiang Chen; Haihua Feng; Terence M Williams; Yuanzhi Lu; Zhengfu He
Journal:  Ann Transl Med       Date:  2021-10

Review 5.  Regulation of DNA duplication by the mTOR signaling pathway.

Authors:  Zhengfu He; Peter J Houghton; Terence M Williams; Changxian Shen
Journal:  Cell Cycle       Date:  2021-03-10       Impact factor: 4.534

6.  Suppression of graft regeneration, not ischemia/reperfusion injury, is the primary cause of small-for-size syndrome after partial liver transplantation in mice.

Authors:  Ning Pan; Xiangwei Lv; Rui Liang; Liming Wang; Qinlong Liu
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.